Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
CG Oncology, Inc. ( (CGON) ) just unveiled an announcement.
CG Oncology reported second-quarter 2026 results on August 6, 2026, highlighting accelerated investment in its cretostimogene program and a strengthened balance sheet. Cash, cash equivalents and marketable securities stood at about $1.0 billion as of June 30, 2026, providing funding runway through 2029, while quarterly R&D and G&A expenses rose sharply year over year, driving a wider net loss of $79.1 million.
Operationally, the company advanced its late-stage bladder cancer pipeline, with Phase 3 PIVOT-006 nearing topline data and BOND-003 Cohort C results published in The Lancet Oncology, bolstering clinical validation for cretostimogene. CG Oncology also secured a legal win in Delaware Superior Court that upheld a favorable jury verdict in its dispute with ANI, preserving a key agreement, and presented additional clinical data from its CORE-008 trial, underscoring its push toward regulatory filings and potential commercialization in high-risk non-muscle invasive bladder cancer.
The most recent analyst rating on (CGON) stock is a Buy
with a $100.00 price target.
To see the full list of analyst forecasts on CG Oncology, Inc. stock,
see the CGON Stock Forecast page.
Spark’s Take on CGON Stock
According to Spark, TipRanks’ AI Analyst, CGON is a Neutral.
The score is primarily held back by weak operating fundamentals—small revenue, negative gross profit, large losses, and heavy cash burn—despite a very strong, low-debt balance sheet that provides flexibility. Corporate events are a secondary positive (governance support and an experienced CFO hire), while valuation is constrained by ongoing losses and technical trend data is unavailable.
To see Spark’s full report on CGON stock,
click here.
More about CG Oncology, Inc.
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing bladder-sparing immunotherapies for patients with bladder cancer. Its lead investigational product, cretostimogene grenadenorepvec, is an intravesically delivered oncolytic immunotherapy being evaluated in multiple Phase 3 and Phase 2 trials in non-muscle invasive bladder cancer, including high-risk, BCG-unresponsive and intermediate-risk patient populations.
Average Trading Volume: 1,051,523
Technical Sentiment Signal: Buy
Current Market Cap: $6.28B
See more insights into CGON stock on TipRanks’ Stock Analysis page.